Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inhaled Murepavadin is an antibiotic targeting pseudomonas aeruginosa in cystic fibrosis, non-CF bronchiectasis. It binds to LptD and inhibits lipopolysaccharide transport function of LptD and causes lipopolysaccharide alterations in the bacterium and ul...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin
Details : The phase I study will evaluate the safety and tolerability of single and multiple ascending doses of inhaled murepavadin in healthy volunteers and will be jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI).
Product Name : POL7080
Product Type : Peptide
Upfront Cash : Inapplicable
December 22, 2020
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Cystic Fibrosis Foundation
Deal Size : $3.3 million
Deal Type : Funding
Details : Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis.
Product Name : POL7080
Product Type : Peptide
Upfront Cash : Undisclosed
November 24, 2020
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Cystic Fibrosis Foundation
Deal Size : $3.3 million
Deal Type : Funding